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ABSTRACT
Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient morbidity and mortality. We
investigated the hepatotoxicity and systems level metabolic phenotype of methotrexate (MTX) in the context of a prevalent
liver disease; non-alcoholic steatohepatitis (NASH). A nuclear magnetic resonance spectroscopic-based metabonomic
approach was employed to analyze the metabolic consequences of MTX (0, 10, 40, and 100 mg/kg) in the urine and liver of
healthy rats (control diet) and in a model of NASH (methionine-choline deficient diet). Histopathological analysis confirmed
baseline (0 mg/kg) liver necrosis, liver inflammation, and lipid accumulation in the NASH model. Administration of MTX (40
and 100 mg/kg) led to liver necrosis in the control cohort, whereas the NASH cohort also displayed biliary hyperplasia and
liver fibrosis (100 mg/kg), providing evidence of the synergistic effect of MTX and NASH. The complementary hepatic and
urinary metabolic phenotypes of the NASH model, at baseline, revealed perturbation of multiple metabolites associated
with oxidative and energetic stress, and folate homeostasis. Administration of MTX in both diet cohorts showed
dose-dependent metabolic consequences affecting gut microbial, energy, nucleobase, nucleoside, and folate metabolism.
Furthermore, a unique panel of metabolic changes reflective of the synergistic effect of MTX and NASH was identified,
including the elevation of hepatic phenylalanine, urocanate, acetate, and both urinary and hepatic formiminoglutamic acid.
This systems level metabonomic analysis of the hepatotoxicity of MTX in the context of NASH provided novel mechanistic
insight of potential wider clinical relevance for further understanding the role of liver pathology as a risk factor for ADRs.
Key words: methionine-choline deficient diet; liver toxicity; methotrexate; metabonomics; nuclear magnetic resonance
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Adverse drug reactions (ADRs) are estimated to be responsible
for approximately 7% of hospital admissions in the USA and
UK (Lazarou et al., 1998; Pirmohamed et al., 2004). Methotrexate
(MTX), a folate analog originally designed to inhibit dihydrofo-
late reductase for leukaemia treatment (Farber et al., 1956), can
cause ADRs including nephrotoxicity and hepatotoxicity (West,
1997; Widemann and Adamson, 2006). The risk of MTX-induced
hepatotoxicity has been shown to increase in the presence of
conditions such as diabetesmellitus or non-alcoholic steatohep-
atitis (NASH), withMTX alone also reported to cause aNASH-like
injury (Langman et al., 2001; Rosenberg et al., 2007).
NASH is an advanced form of non-alcoholic fatty liver dis-
ease characterized by inflammation, macrovesicular steatosis,
oxidative stress, and insulin resistance (Brunt, 2004). It is esti-
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mated to affect approximately 12% of USA adults, and approxi-
mately 20% of NASH sufferers develop liver cirrhosis (Williams
et al., 2011). The development of NASH is believed to involve
a first hit, which is the result of imbalanced fat metabolism,
and a second hit that involves metabolic and oxidative stress
(Day and James, 1998). NASH has also been shown to influence
hepatic drug metabolism by affecting CYP 450 enzyme activity
(Fisher et al., 2009) and ATP-binding cassette transporters (Hard-
wick et al., 2011) and could therefore increase the risk of ADR
occurrence.
NASH is modeled in vivo using several methods that include
the use of specific diets or genetic models (Larter and Yeh, 2008).
The methionine-choline deficient (MCD) diet has been widely
employed to model NASH as it leads to a condition character-
ized by steatosis, mitochondrial dysfunction, inflammation, and
oxidative stress (Rinella et al., 2008; Rizki et al., 2006). Moreover,
increased CYP 2E1 expression (Leclercq et al., 2000) and downreg-
ulation of stearoyl-CoA desaturase-1 (SCD-1) (Rizki et al., 2006)
have also been reported, all of which reflect the clinical NASH
phenotype. However, the MCD model fails to recapitulate the
metabolic syndrome component of NASH as it does not induce
obesity, insulin resistance, or hyperglycemia (Larter and Yeh,
2008).
Metabonomics is a top-down untargeted systems approach
that has been widely applied to characterize metabolic profiles
of biofluids or tissues in disease states or in response to toxic in-
terventions (Nicholson et al., 1999). Metabonomic analysis typi-
cally relies on nuclear magnetic resonance (NMR) spectroscopy
and mass spectrometry to generate high-resolution metabolic
profiles. Statistical pattern recognition tools including principal
components analysis (PCA) and orthogonal partial least squares
discriminant analysis (O-PLS-DA) are applied to model the mul-
tivariate data (Fonville et al., 2010). Metabonomics has been pre-
viously employed to investigate the serum metabolic effects
of MTX in rheumatoid arthritis patients, where endogenous
metabolic markers capable of predicting response to MTX treat-
ment were identified, which included amino acids, taurine, and
uracil (Wang et al., 2012). It has also been applied to characterize
the clinical NASH lipidomic plasma signature (Puri et al., 2009),
togetherwith the serummetabolic phenotype of theMCDmodel
of NASH in mice (Tanaka et al., 2012), which revealed disruption
of phospholipid and bile acid homeostasis.
In the present study, we employed a metabonomic approach
to investigate the dose and time-dependent systemic endoge-
nous and xenobiotic metabolic phenotype of MTX in the urine
and liver of healthy animals and in the context of NASH, asmod-
eled by the MCD diet.
MATERIALS AND METHODS
Animal husbandry and MTX administration. This study was ap-
proved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Arizona, and is in accordance with
NIH guidelines for the care and use of experimental animals.
Male Sprague Dawley rats (weighing 200–250 g prior to the begin-
ning of the experiment, n = 44; Harlan Laboratories, Indianapo-
lis, IN, USA) were randomly split into two groups (n = 22) which
were either fed ad libitum a choline sufficient and amino-acid
defined diet or the equivalent methionine-choline deficient diet
(Dyets Inc, Bethlehem, PA) and tapwater, for a period of 8 weeks.
The rats were acclimated to 12-hour light and dark cycles in an
AAALAC-accredited animal facility for 1 week prior to the ini-
tiation of experiments. The rats in each diet group were then
randomly assigned to be administered 10, 40, and 100 mg/kg of
MTX dissolved in 0.3-M sodium bicarbonate (Toronto Chemicals,
Toronto, Canada) or vehicle (0.3 M sodium bicarbonate) via a sin-
gle intra-peritoneal injection.
Sample collection. Urine samples were collected at 0 h (pre-dose,
−6 to 0-hour collection; 0 h) and across the following time pe-
riods 6–12 (12 h), 18–24 (24 h), and 36–48 (48 h) hours post-dose
viametabolism cages into 50-ml tubes on ice containing sodium
azide (1 ml, 1% w/v in water). At each time point, the urine was
transferred to a clean 50-ml conical tube and immediately stored
at −80◦C. At 96-hours post-dose (96 h), animals were euthanized
via CO2 asphyxiation and livers were immediately snap-frozen
in liquid nitrogen and stored at −80◦C until analysis.
Liver histopathology and imaging. Liver tissue for histomorpho-
logic examination was taken from the medial lobe of each ani-
mal, fixed in 10% neutral-buffered formalin for 24 h, then placed
in 70% ethanol until paraffin embedding and hematoxylin and
eosin (H&E) staining. Masson Trichrome staining was also per-
formed using the Masson Trichrome Kit from Sigma-Aldrich (St.
Louis, MO) per manufacturer’s instructions. All slides were im-
aged with a Leica DM4000B microscope, DFC450 camera, and
Leica Application Suite software (Leica Microsystems, Wetzlar,
Germany). Sections were examined by light microscopy by a
board certified blinded veterinary pathologist (Burkhardt et al.,
2011). Liver necrosis, inflammation, fibrosis, lipid accumulation,
and biliary hyperplasia were scored. The scoring criteria were as
follows: 0 (no lesion), 1 (10% lesion; minimal), 2 (10–25% lesion;
mild), 3 (25–40% lesion; moderate), 4 (40–50% lesion; marked),
and 5 (50% lesion; severe). Representative histology images
were acquired with a Leica DM4000B microscope, DFC450 cam-
era, and Leica Application Suite software (Leica Microsystems).
Sample preparation and 1H-NMR spectroscopy of hepatic aqueous-
soluble extracts. Liver metabolite extraction and 1H-NMR spec-
troscopy of the hepatic aqueous-soluble extracts was performed
as previously described (Beckonert et al., 2007). Briefly, liver
tissue samples (mean 52.5 mg, STD ± 0.73) were added to
acetonitrile/water (1.5 ml, 1:1). The samples were homogenized
with zirconia beads in a homogenizer (Qiagen Tissue Lyser,
Retsch GmBH, Haan, Germany) at 6500 Hz for two 45-s peri-
ods, with an intermediate 5-min cooling period on dry ice. The
samples were then kept on ice for 45 min prior to centrifuga-
tion at 17,000 × g for 15 min at 4◦C. The supernatants were
concentrated and dried overnight in a centrifugal evaporator
(SpeedVac, Thermoscientific, Waltham, MA) at room tempera-
ture. The dried supernatants were reconstituted in phosphate
buffer (600 l of a 0.2-M solution) containing 100% D2O, sodium
azide (NaN3, 3mM), and 3-(trimethylsilyl)-[2,2,3,3–2H4]-propionic
acid sodium salt (TSP; 1mM)), vortexed for 30 s and then cen-
trifuged at 17,000 × g for 15 min at 4◦C. The supernatants (550
l) were transferred to 5-mm NMR tubes (NMR Precision tube
507-HP-7, Norell, Landisville, NJ). NMR spectral data were ac-
quired on a Bruker Avance-600 spectrometer (Bruker Biopsin,
Rheinstetten, Germany) operating at 600.13-MHz (14.1 T) 1H fre-
quency and at a temperature of 300 K, using a Bruker TXI probe
and an automated sample handling carousel (Bruker). A stan-
dard one-dimensional solvent suppression pulse sequence was
used to acquire the free induction decay (FID; relaxation delay −
90◦ pulse − 4-s delay − 90◦ pulse − mixing time − 90◦ pulse −
acquire FID) (Beckonert et al., 2007). For each experiment, 64 tran-
sientswere collected into 64-k data points using a spectral width
of 12,000 Hz, with a relaxation delay of 4 s, an acquisition time of
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2.7 s, and a mixing time of 100 ms. A Carr-Purcell-Meiboom-Gill
(CPMG) spin-echo pulse sequence, with a fixed spin-spin relax-
ation delay 2nτ of 240 ms (n = 300, τ = 400 s), was also used to
acquire the FID (relaxation delay − 90◦ pulse − (t − 180◦ − t)n −
acquire FID) (Beckonert et al., 2007). The CPMG pulse sequence
is used to attenuate signals from large macromolecules such as
lipids and proteins. Three hundred and eighty four transients
were collected into 64-k data points using a spectral width of
12,000 Hz, with a relaxation delay of 4 s and an acquisition time
of 2.7 s. The D2O present in the buffer provided a field frequency
lock, whereas TSP served as the chemical shift reference. A line-
broadening factor of 0.3 Hz was applied to all spectra prior to
Fourier Transformation (FT).
1H-NMR spectroscopy of urine. 1H-NMR spectroscopy of urine
was performed as previously described (Beckonert et al., 2007).
Briefly, urine was mixed with phosphate buffer (2:1; 600 l to-
tal volume; 0.2 M as above) and vortexed for 1 min. The sam-
ples were then centrifuged at 17,000 × g for 15 min at 4◦C. The
resulting supernatants (550 l) were then transferred to 5-mm
NMR tubes (507-HP-7). NMR spectral data were acquired on a
Bruker Avance-600 spectrometer operating at 600.13-MHz (14.1
T) 1H frequency and at a temperature of 300 K using a Bruker TXI
probe and an automated sample handling carousel (Bruker). A
standard one-dimensional solvent suppression pulse sequence
was used to acquire the FID as described above. For each exper-
iment, 320 transients were collected into 64-k data points us-
ing a spectral width of 12,000 Hz, with a relaxation delay of 4 s,
an acquisition time of 2.7 s, and mixing time of 100 ms. A line-
broadening factor of 0.3 Hz was applied to all spectra prior to
FT.
The NMR spectra were initially processed using TopSpin 3.0
NMR software (Bruker), where theyweremanually phased, base-
line adjusted, and referenced to the TSP resonance at 0 ppm.
Full-resolution NMR data were imported into MATLAB (R2012,
Mathworks Inc., Natick, MA), using an in-house script, for fur-
ther processing. This included the removal of the TSP, MTX
related and water resonances in the hepatic aqueous-soluble
component spectra and the TSP, MTX related, urea and wa-
ter resonances from the urine spectra. Probabilistic quotient
normalization and spectral alignment were performed in each
diet cohort data set separately, apart from when performing
the diet baseline comparison (using an in-house script) (Di-
eterle et al., 2006). Spectral assignments were performed us-
ing Statistical TOtal Correlation Spectroscopy (STOCSY) (Cloarec
et al., 2005), spectral databases (in-house, Human Metabolome
Database and Biological Magnetic Resonance Bank), Chenomx
NMR Suite (Chenomx, Edmonton, Alberta, Canada), and previ-
ously published assignments (Nicholson et al., 1995;Waters et al.,
2005). The assignments of uracil, hypoxanthine, inosine, uridine,
maltose, mannose, choline, phosphocholine, and glycine in the
hepatic aqueous-soluble extracts and dimethylamine, methy-
lamine, phenylacetylglycine, putrescine, 3-indoxylsulphate, tar-
trate, glucosan, and taurine in the urine were confirmed by ad-
dition of the pure standard compounds. Please note that glu-
tathione refers to total glutathione (sumof oxidized and reduced
glutathione). The CPMG spectra of the hepatic aqueous-soluble
extracts were acquired and modeled in order to minimize the
contribution from lipids that arose from the MCD diet cohort.
The urinary excretion ofMTX following administration of 100
mg/kg in both diet cohorts was calculated by performing local
baseline correction prior to integration of the MTX resonance at
8.63 ppm in TopSpin. The integral of TSP (which was of known
concentration) and the excreted urine volumes per rat at each
time point were used to calculate the urinary amount of MTX (in
micrograms). The results were verified independently by mass
spectrometry (R  0.99).
Statistical analysis. Multivariate statistical tools were employed
to analyze the 1H-NMR data from both the urine and hepatic ex-
tracts. PCA was initially applied to investigate the baseline diet
comparison and the effect of MTX by characterizing the inher-
ent clustering of the data and the presence of potential outliers
(Fonville et al., 2010). O-PLS-DA was subsequently performed,
which discriminated the pre-dose and post-dose groups. O-PLS-
DA filters out variation that is orthogonal to class membership
and hence improves model interpretability. In order to avoid
over-fitting the data, a 7-fold cross-validation was used and sta-
tistical parameters (R2Y and Q2Y representing the goodness of
fit and predictive ability) were calculated (Fonville et al., 2010).
Permutation tests (n = 1000 permutations of the class member-
ship) were also used to test the validity of eachmodel. Heatmaps
based on the Pearson correlation coefficient values (R) of the
identified discriminatory resonances from the O-PLS-DA mod-
els were also constructed with a cut-off R value of |0.5|. Prism 5.0
(Graphpad; La Jolla, CA) was used for non-parametric univariate
analysis (Kruskal-Wallis with Dunn’s multiple correction test). A
significance threshold value of p  0.05 was set throughout.
RESULTS
Liver Histopathology
Histopathological assessment of the control diet cohort revealed
hepatic necrosis following MTX treatment (40 and 100 mg/kg;
Figs. 1A and 2). In the control diet cohort, one animal also de-
veloped liver inflammation and another biliary hyperplasia fol-
lowing MTX treatment (40 and 100 mg/kg, respectively; Figs.
1C and E, respectively). In contrast, the MCD diet cohort had a
background (vehicle group) characterized by liver necrosis, lipid
accumulation, and liver inflammation (Figs. 1A–C, respectively,
and Fig. 2). Following treatment of theMCDdiet cohortwithMTX
(40 mg/kg), a statistically significant reduction in lipid accumu-
lation and liver inflammation was observed (Figs. 1B and C, re-
spectively, and Fig. 2). The MCD diet cohort rats also developed
minimal liver fibrosis and mild biliary hyperplasia (black arrow,
Fig. 2) following treatment with the highest dose of MTX (100
mg/kg; Figs. 1D and E, respectively).
Body weight was monitored at the beginning and end of the
study. The average baseline weight of the control diet cohort an-
imals was 390 g (STD± 57 g) whereas that of theMCD diet cohort
was 200 g (STD± 46 g). In the control diet cohort, weight loss was
observed following administration of MTX with an average per-
centage weight loss of 7%, 16%, and 26% for the cohorts admin-
istered 10, 40, and 100-mg/kg MTX, respectively. The MCD diet
cohort also experienced weight loss with an average percentage
weight loss of 18%, 20%, and 20% for the cohorts administered
10, 40, and 100-mg/kg MTX, respectively (Supplementary fig. 1).
Hepatic and Urinary Metabolic Phenotype of the NASH Model (MCD
Diet Cohort Baseline)
Pair-wise O-PLS-DA models were computed to identify the dis-
criminatory metabolites between the two diet cohorts for each
biological matrix. A robust O-PLS-DA model (Fig. 3A; R2Y =
0.9913, Q2Y = 0.9315, and p = 0.009) revealed complete differ-
entiation between the hepatic aqueous-soluble extract baseline
(vehicle) metabolic profiles of the two diet cohorts as evidenced
from the cross-validated predictive component of the scores
plot (Tcv, cross-validated predictive scores; Fig. 3A1). The cor-
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FIG. 1. Histopathology scores representing liver necrosis (A), lipid accumulation (B), liver inflammation (C), liver fibrosis (D), and biliary hyperplasia (E) (average and
standard deviation) following administration of MTX (vehicle, 10, 40, and 100 mg/kg) in both the control and MCD diet cohorts. Statistical significance is indicated by
one or two asterisks representing p  0.05 and p  0.01, respectively. There are five animals per group apart from the 100-mg/kg dose in the MCD diet cohort which
has six. The scoring criteria are: 0 = no significant lesions; 1 = minimal; 2 = mild; 3 = moderate; 4 = marked; and 5 = severe. Veh: vehicle.
responding coefficient plot (Fig. 3A2) showed that the metabolic
signature of the MCD diet cohort included depleted levels of glu-
cose, glycogen, mannose, maltose, glutathione, lactate, niaci-
namide, choline, phosphocholine, trimethylamine, tyrosine, 1-
methylhistidine, inosine, and uridine, together with elevated
levels of glycine, lipids, fumarate, and formiminoglutamic acid
(FIGLU), with respect to the baseline control diet cohort.
The O-PLS-DA model comparing the urinary baseline (pre-
dose, 0 h) metabolic profiles of the two diet cohorts (Fig. 3B; R2Y
= 0.9519, Q2Y = 0.9040, and p = 0.001) indicated complete dis-
crimination as evidenced from the scores plot (Tcv; Fig. 3B1). The
corresponding coefficient plot (Fig. 3B2) indicated that, relative
to the control diet, the MCD diet cohorts had elevated levels of
citrate, urocanate, guanidinoacetate, methylamine, taurine, for-
mate, and FIGLU, and depleted levels of trimethylamine-N-oxide
(TMAO) and dimethylamine.
Hepatic Metabolic Phenotype Following MTX Administration in the
Control Diet Cohort
O-PLS-DA pair-wise models were employed to characterize the
metabolic consequences of MTX administration on the hepatic
aqueous-soluble extract metabolic profiles of the control diet
cohort, relative to the vehicle cohort. The statistically robust
O-PLS-DA model characterizing the effect of 100-mg/kg MTX
administration (Fig. 4A; R2Y = 0.9985, Q2Y = 0.8485, and p =
0.009) achieved complete separation between the two groups
in the scores plot (Tcv; Fig. 4A1). The corresponding coeffi-
cient plot (Fig. 4A2) revealed that the administration of 100-
mg/kg MTX led to the depletion of lactate, glucose, maltose,
mannose, glycogen, betaine, inosine, dimethylamine, and glu-
tathione. It also led to the concomitant rise in the levels of va-
line, glutamate, leucine, isoleucine, glycerophosphocholine, D-
3-hydroxybutyrate, formate, uracil, hypoxanthine, creatine, and
choline following MTX administration relative to the vehicle co-
hort.
The O-PLS-DA models comparing the hepatic metabolic pro-
files of the vehicle with the 10- and 40-mg/kg MTX administra-
tion groups (Supplementary fig. 2) were statistically robust and
identified a panel of discriminatory metabolites for each dose
group, including an elevation of glutamate, valine, isoleucine,
leucine, and uracil, together with depletion of betaine, glu-
tathione, dimethylamine, glycogen, and glucose, relative to the
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FIG. 2. (A) Representative histology images of H&E-stained control and MCD
liver sections following vehicle or 10, 40, or 100-mg/kg MTX and (B) Masson
Trichrome stained liver sections following 100-mg/kg administration in both di-
ets (×20 magnification). White and cyan arrows indicate inflammation and sin-
gle cell necrosis in the MCD diet cohort baseline respectively. Black and red ar-
rows indicate biliary hyperplasia and liver fibrosis, respectively, in the MCD co-
hort following administration of MTX (100 mg/kg).
control cohort. The scale of metabolic perturbations induced by
MTX administration was progressive and was maximal at the
highest dose (100 mg/kg). Hepatic changes reflective of a dose
response included elevation of valine, isoleucine, leucine and
depletion of glucose, dimethylamine, glycogen, and glutathione.
Furthermore, a number of unique metabolic changes were ob-
served specific to the administration of 100-mg/kg MTX relative
to the vehicle, which included increased levels of hypoxanthine,
formate, and creatine. A summary of the hepatic metabolic ef-
fects induced by MTX administration at all doses in the control
diet cohort is presented in Fig. 5A in the form of a heatmap,
which displays the given R for each discriminatory metabolite
obtained from the O-PLS-DA coefficients.
Hepatic Metabolic Phenotype Following MTX Administration in
the MCD Diet
O-PLS-DA pair-wise models were computed to identify the
discriminatory metabolites related to the effect of MTX admin-
istration at each dose level (10 mg/kg, 40 mg/kg, and 100 mg/kg)
relative to the vehicle group in the MCD diet cohort. The sta-
tistically robust O-PLS-DA model of the vehicle and 100-mg/kg
MTX administration group of the MCD diet cohort (Fig. 4B; R2Y=
0.9957, Q2Y= 0.9155, and p= 0.001) differentiated completely be-
tween the two groups (Tcv; Fig. 4B1). The corresponding coef-
ficient plot (Fig. 4B2) indicated that the administration of 100-
mg/kg MTX led to the rise of the levels of uracil, fumarate,
D-3-hydroxybutyrate, valine, leucine, phenylalanine, glutamate,
creatine, choline, urocanate, FIGLU, formate, and niacinamide,
whereas inosine, phosphocholine, lactate, glycogen, maltose,
and glucosewere depleted. The increase in fumaratewas unique
to the model characterizing the effect of high dose MTX admin-
istration (100 mg/kg) in the MCD diet cohort. Significant hepatic
metabolic perturbations were also identified following adminis-
tration of both 10- and 40-mg/kg MTX including the depletion
of glucose, maltose, and glycogen, and the elevation of leucine,
isoleucine, glutamate, uracil, and FIGLU. The scale of metabolic
change was reflective of the dose response with respect to an
increase in phenylalanine, acetate, glutamate, and FIGLU and
decrease in lactate levels. A summary of the hepatic metabolic
effects induced by MTX administration at all doses for the MCD
diet cohort is presented in Fig. 5B. Elevation of phenylalanine
was also observed to be statistically significant in a regression
analysis of the hepatic aqueous-soluble extract metabolic pro-
files from both diet cohorts with the biliary hyperplasia and
fibrosis scores (R2Y= 0.5218, Q2Y= 0.2423, and p= 0.020, and
R2Y= 0.5406, Q2Y= 0.2542 and p= 0.014, respectively). Integra-
tion of the phenylalanine resonance showed a statistically sig-
nificant elevation following administration of 100-mg/kg MTX
in the MCD diet cohort, when compared with the vehicle cohort,
confirming theO-PLS regression results (p= 0.02; Supplementary
fig. 3).
Urinary Metabolic Phenotype Following MTX Administration in the
Control Diet
The collection of urine samples at sequential time points fa-
cilitated the characterization of the temporal metabolic conse-
quences ofMTX at each dose level for each diet cohort. O-PLS-DA
pair-wise models were constructed to investigate the differenti-
ation of pre-dose urinary baseline metabolic profiles (0 h) and
post-treatment metabolic profiles (12 h, 24 h, and 48 h). The O-
PLS-DA models that discriminated the metabolic effect of the
100-mg/kg dose of MTX from baseline had the highest statisti-
cal significance and greatest predictive ability andwill be further
discussed.
The O-PLS-DA models characterizing the comparison of the
urine pre-dose (0 h)metabolic profileswith each of the post-dose
(100-mg/kg MTX) time points (12 h, 24 h, and 48 h) in the con-
trol diet cohort showed that as time progressed, the effect of
MTX became more pronounced (for a summary of the statisti-
cal parameters for each model please see Supplementary table
1). The statistically robust model comparing the metabolic pro-
files of the control diet 0-h and 48-h time points (Fig. 6A; R2Y
= 0.9859, Q2Y = 0.7608, and p = 0.034) achieved complete sepa-
ration between the two groups in the scores plot (Tcv; Fig. 6A1).
The corresponding coefficient plot (Fig. 6A2) revealed a depletion
of alanine, methylamine, dimethylamine, hippurate, TMAO, and
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FIG. 3. Hepatic aqueous-soluble extracts (A1, A2) and urinary (B1, B2) O-PLS-DA models distinguishing between the baseline of the control and MCD diet cohort. The
scores plots (A1 and B1) depict the separation of the MCD (red; n = 5 in the liver and n = 20 in the urine) and control diet cohort (black; n = 5 in the liver and n = 20
in the urine) in multivariate space. Tcv is the predictive component, whereas TYosc is the orthogonal component. The loadings coefficient plots (A2 and B2) illustrate
the discriminatory spectral resonances with the height of spectral peaks representing covariance. The color-scale corresponds to the coefficient of determination
(R2) ranging from low (0; blue) to high (red; 1). Resonances pointing upward indicate an increase in that specific resonance in the control cohort and vice versa.
FIGLU—formiminoglutamic acid; Choline-NMe3—NMe3 resonance of choline, phosphocholines and glycerophosphocholines; TMAO—trimethylamine-N-oxide.
3-indoxylsulfate, together with an elevation of the levels of suc-
cinate, creatine, phenylacetylglycine, and formate.
Urinary Metabolic Phenotype Following MTX Administration in the
MCD Diet
The corresponding urinary analysis of the metabolic effect of
MTX administration (100 mg/kg) in the MCD diet cohort also in-
dicated a time-dependent progressive effect of MTX that was
maximal at 48 h post-treatment (Supplementary table 1 pro-
vides a summary of the statistical parameters of the models).
The statistically robust model comparing the metabolic profiles
of the MCD diet 0-h and 48-h time points (Fig. 6B; R2Y = 0.9985,
Q2Y = 0.8485, and p = 0.001) achieved complete differentiation
between the two groups in the scores plot (Tcv; Fig. 6B1). The
equivalent coefficient plot (Fig. 6B2) indicated that MTX admin-
istration led to an elevation in the levels of FIGLU and formate,
and the depletion of methylamine, alanine, and hippurate.
Following administration of MTX (100 mg/kg), the urinary
metabolic phenotype showed a progressive depletion from 12
h to 48 h of methylamine and hippurate and elevation of for-
mate and FIGLU. The depletion of alanine at 48 h was a unique
metabolic effect that was specific for this time point. Depletions
in the levels of 3-indoxylsulfate and phenylacetylglycine were
also observed but these were restricted to the 24-h time point,
whereas TMAO was depleted in both 12 h and 24 h but had
returned to baseline levels by 48 h. With respect to the mod-
els characterizing the metabolic effect of the 10-mg/kg and 40-
mg/kg doses of MTX, elevation of FIGLU and formate was also
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FIG. 4. Hepatic extract O-PLS-DAmodels comparing the vehicle cohorts and 100-mg/kg MTX administration cohorts in the control diet (A1 and A2; n = 5 for the vehicle
group and n = 5 for the MTX dosed group) andMCD diet (B1 and B2; n = 5 for the vehicle group and n = 6 for the MTX doses group). The score plots (A1 and B1) depict the
separation of the MTX dose (red) and vehicle (black) cohorts in multivariate space. Key: See the legend of Fig. 3. DMA: dimethylamine; D-3-HB: D-3-hydroxybutyrate;
Asterisks: FIGLU formiminoglutamic acid.
observed at 48 h post-dose. However, at that time point, both of
the lower doses of MTX also led to the depletion of methylamine
and 3-indoxylsulfate, together with the elevation of dimethy-
lamine, all ofwhichwere not observed at the corresponding time
point after 100-mg/kg MTX administration.
The comparison of the effects of administration of MTX (100
mg/kg) in the two diet cohorts showed several diet specific
MTX-induced metabolic effects. At 48 h post-dose, elevations of
phenylacetylglycine, creatine, citrate, and succinate were spe-
cific only to the control diet cohort, whereas elevated levels of
FIGLUwere specific only to the MCD diet cohort (Fig. 7 illustrates
a heatmap summary of the urinary metabolic effect of MTX ad-
ministration (100 mg/kg) in both diet cohorts).
Finally, temporal urinary levels of the MTX parent compound
following administration of the 100-mg/kg dose were also com-
pared between the two diet cohorts at the 12-h, 24-h, and 48-h
time points. The levels of MTX were greater in the control diet
cohort than the MCD cohort at all time points, reaching statisti-
cal significance at the 48-h time point (p = 0.0025; Supplemen-
tary fig. 4).
DISCUSSION
Characterization of the MCD Diet Model of NASH
The MCD diet had liver histopathology consistent with a phe-
notype reflective of clinical NASH (Brunt, 2004). Metabonomic
analysis of the hepatic extracts and urine from the MCD diet
cohort indicated a general impairment of energy and choline
metabolism, coupled with glutathione depletion. The depletion
of energy metabolites such as hepatic glucose and glycogen, rel-
ative to the control diet cohort, is indicative of energetic stress
and could be related to the previously reported NASH-induced
mitochondrial stress (Perez-Carreras et al., 2003) or the inhibition
of SCD-1 (Rizki et al., 2006). Glutathione depletion is a marker of
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FIG. 5. Heatmap describing the hepatic metabolic effects of MTX administration in the control diet (A) and MCD diet (B). The heatmap was constructed using the
maximum Pearson correlation coefficient values (R) for eachmetabolite from the hepatic extract O-PLS-DAmodels distinguishing themetabolic profiles of MTX treated
(10, 40, 100 mg/kg) and the vehicle cohort, in the control diet (A) and MCD diet (B). The scale shown on the right has a range from −1 (perfect negative correlation; blue
color) to 1 perfect positive correlation; red color), whereas a cut-off value of |0.5| was set. Key: See the legend of Fig. 4.
oxidative stress which is also characteristic of the NASH back-
ground (Merrell and Cherrington, 2011) and whose hepatic de-
pletion was also potentially exacerbated by themethionine defi-
cient nature of theMCD diet. Finally, the choline deficient nature
of the diet was also likely to be directly linked to the depletion
of choline-related metabolites such as hepatic trimethylamine
and choline and urinary TMAO.
The choline and methionine deficient nature of this dietary
model would have also directly impaired the folate cycle and
one-carbon metabolism (Fig. 8). Impairment of the folate cycle
would lead to reduced tetrahydrofolate (THF) production, which
may explain the observed accumulation of urinary and hepatic
FIGLU and urocanate and urinary formate. THF is required for
the conversion of FIGLU to glutamate and FIGLU is a previously
described urinary marker of folate deficiency (Rabinowitz and
Tabor, 1958). Accumulation of urinary formate would arise from
THF depletion and the subsequent impairment of formyl-THF
production. Finally, the depleted levels of hepatic inosine and
the elevated levels of hepatic glycine and urinary guanidinoac-
etate (a glycine metabolite) may also be linked to a general inhi-
bition of the folate cycle (Fowler, 2001).
It is important to be aware of the limitations associated with
theMCD diet as amodel of NASH. Creation of amodel that accu-
rately reflects the clinical condition of NASHhas proven difficult,
because it would require replication of both the liver pathology
and the systemic metabolic environment (Larter and Yeh, 2008).
The MCD diet is believed to induce steatohepatitis and oxidative
stress through the inhibition of phosphatidylcholine synthesis
and impairment of hepatic lipid transport (Rinella et al., 2008),
but it is not thought to be an accurate reflection of themetabolic
syndrome component of NASH because it does not induce obe-
sity, insulin resistance, or hyperglycemia. Furthermore, theMCD
diet induces significant weight loss as was also observed in our
study (Larter and Yeh, 2008; Rinella et al., 2008).
Effect of MTX in the Context of the Control Diet Cohort
Minimal liver necrosis was observed following administration of
MTX (40 and 100mg/kg) in the control diet cohort. Metabonomic
analysis showed dose-related metabolic consequences in both
sample matrices, together with a temporal effect in the case of
urinary metabolic profiles.
The MTX-induced elevation of the levels of hepatic uracil
is potentially due to the inhibition of thymidylate synthetase,
whereas the observed depletion of hepatic inosine could re-
sult from the inhibition of phosphoribosylaminoimidazolecar-
boxamide formyltransferase (Genestier et al., 2000). MTX could
also affect the levels of nucleobases and nucleosides indirectly
through the disruption of the folate cycle and its inhibition
of THF formation, which could have other downstream conse-
quences such as the observed elevation of urinary formate.
The observed effect of MTX, consistent at all doses, on hep-
atic energy metabolism, including the depletion of lactate, glu-
cose, and glycogen, could be attributed to the previously re-
ported inhibition of oxidative phosphorylation, which would
lead to a higher utilization of glucose through other pathways
(Yamamoto et al., 1988). Furthermore, the depletion of the afore-
mentioned metabolites could lead to lipid breakdown, as indi-
cated by the elevated levels of hepatic D-3-hydroxybutyrate. This
observed disturbance of energymetabolism could also be linked
to a reduced caloric intake through the previously reportedMTX-
induced weight loss, which is linked to a disruption of gut ab-
sorption and mucositis (Naruhashi et al., 2000). A reduction of
caloric intake could also be linked to the observed depletion of
hepatic glutathione (Szkudelski et al., 2004) and choline-related
moieties, such as hepatic phosphocholine and dimethylamine.
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FIG. 6. Urinary O-PLS-DA models comparing the pre-dose time point and the 48-h post-dose time point after 100-mg/kg MTX administration in the normal diet (A1
and A2; n = 4 at 0 h and n = 5 at 48 h) and MCD diet (B1 and B2; n = 6 at 0 h and n = 7 at 48 h). Key: See the legend of Fig. 3.
FIG. 7. Heatmap describing the urinary metabolic effects of MTX administration in the control diet (A) andMCD diet (B). Based on O-PLS-DAmodels that discriminated
between the metabolic profiles of the post-dose time points (12 h, 24 h, and 48 h) of MTX administration (100 mg/kg) and the pre-dose time point (0 h), in both diets.
Key:See the legend of Fig.3. Phenylacetyl-G: phenylacetylglycine.
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FIG. 8. A simplified diagrammatic representation of the interaction of themethionine cycle (blue), folate cycle (black), choline catabolism (red), and histidine catabolism
(orange) pathways is depicted above. (1) reveals where the choline catabolism pathway interacts with the methionine cycle, (2) indicates the point at which the
methionine and folate cycles interact, (3) shows the metabolic reaction inhibited by methotrexate, and (4) indicates how the folate cycle can directly influence the
histidine catabolism pathway. THF: tetrahydroflate; DHF: dihydrofolate; FIGLU: formiminoglutamic acid.
However, a previous metabolic profiling investigation of caloric
restriction observed a different panel of discriminatory urinary
metabolites to that of our investigation (Connor et al., 2004). Nev-
ertheless, it is recommended that future studies should also
record food consumption and employ an experimental design
that would incorporate a pair feeding system in order to be able
to easily identify any metabolic changes linked to fasting.
Effect of MTX in the Context of the NASH Background (MCD Diet
Model)
We hypothesized that the presence of the NASH background,
which can induce changes in drug metabolizing enzymes and
hepatic transporters (Fisher et al., 2009; Hardwick et al., 2011),
would alter MTX-induced metabolic consequences and toxic
outcome. The administration of MTX (40 mg/kg) in the context
of NASH resulted in a statistically significant histomorphologic
reduction of lipid accumulation and inflammation. These ob-
served reductions are suggestive of a protective effect due to the
anti-inflammatory properties of MTX, whereas MTX has previ-
ously been reported to affect cholesterol transport (Coomes et al.,
2011). However, administration of the highest dose caused min-
imal liver fibrosis and biliary hyperplasia suggesting enhanced
toxicity of MTX in the context of NASH.
Metabonomic analysis of the hepatic aqueous-soluble ex-
tracts revealed that, in part, the metabolic effect of MTX in the
NASHmodel had a similar progressive pattern to the control diet
cohort. Interestingly, MTX-induced metabolic effects specific to
the NASH model were also observed, suggesting that the NASH
baseline influenced themetabolic consequences of MTX admin-
istration. These included increased levels of hepatic FIGLU, uro-
canate, phenylalanine, acetate, niacinamide, and fumarate. The
progressive dose-dependent elevations of fumarate, phenylala-
nine, and niacinamide did not follow the same pattern as the ob-
servedweight loss in theMCDdiet cohort and therefore aremore
likely to be mechanistically indicative of MTX toxicity and not a
direct consequence of either MTX or MCD-diet-induced weight
loss. The elevations of hepatic metabolites associated with the
folate cycle, such as FIGLU andurocanate, followingMTXadmin-
istration in the NASH model are signs of a significant inhibition
of the folate cycle, greater than that observed in the MCD diet
at baseline and greater than that observed after MTX adminis-
tration in the control diet cohort. This combined effect of MTX
andNASH, coupled to previous clinical reports of NASH-induced
methionine cycle disruption triggered through glutathione de-
pletion (Kalhan et al., 2011), suggests a clinically relevant syner-
gistic effect of NASH and MTX on folate metabolism (Fig. 8).
Hepatic phenylalaninewas also identified by regression anal-
yses as the sole endogenous metabolite associated with the
development of biliary hyperplasia and liver fibrosis. Levels of
hepatic phenylalanine are used as a liver function test because
they are related to the activity of the phenylalanine hydroxy-
lase enzyme, an important enzyme for phenylalanine degrada-
tion (Burke et al., 1997). Higher levels of serum phenylalanine
have been previously reported clinically following treatment
with MTX and were linked to the inhibition of dihydropteridine
reductase (Hilton et al., 1989). However, the observed elevation of
hepatic phenylalanine in our study is likely to be influenced by
additionalmechanisms because the levels of hepatic tyrosine re-
mained unperturbed. Furthermore, the levels of urinary pheny-
lacetylglycine following administration of 100-mg/kgMTX in the
MCD diet cohort were also largely unperturbed during the time
course of the study.
The parallel study of the xenobiotic metabolic profile en-
abled characterization of the effect of NASH on the disposition
of MTX and showed increased urinary excretion of MTX in the
control cohort at the 12-h, 24-h, and 48-h time points. This is
explained by the greater urinary excretion of MTX that was ob-
served for the MCD diet cohort relative to the control diet co-
hort within the first 6 h post-dose (Hardwick et al., in prepara-
tion). The observed higher early urinary excretion of MTX in the
MCD diet cohort could be due to the reported downregulation of
canalicular transporters in the NASH model, and the relatively
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lower quantity of MTX in the feces, which indicate a shift in
the excretion pathway of MTX toward urinary excretion (Hard-
wick et al., in preparation). Furthermore, a previous study has
also reported the downregulation of uptake transporter genes in
disease-compromised livers as a hepatoprotective mechanism,
indicating another potential mechanism behind the observed
difference of urinary MTX excretion (Lake et al., 2011).
Effect of MTX on Gut Microbial Co-metabolites
High dose MTX can cause intestinal toxicity and it has also been
shown to affect the intestinal microbial composition (Naruhashi
et al., 2000). BothMTX (100mg/kg) diet cohorts displayedmild in-
flammation andminimal apoptosis in the small intestine (Hard-
wick et al., in preparation). Metabonomic analysis indicated that
gut microbial co-metabolites, including urinary methylamine,
TMAO, and 3-indoxylsulfate, were depleted in both diet cohorts
following administration of 100-mg/kg MTX suggesting a poten-
tial perturbation of the gut microfloral balance (Nicholson et al.,
2012).
SUMMARY
This systems level data analysis provided enhanced mechanis-
tic phenotyping of a widely used model of NASH, revealing a
metabolic phenotype characterized by energetic and oxidative
stress, and further contextualized its application in experimen-
tal studies. Metabolic profiling of the hepatic and urinary dose
and temporal response to MTX administration revealed a wide
panel ofmetabolic consequences that provided novelmechanis-
tic insight. Finally, the administration of MTX (100 mg/kg) in the
context of NASH led to enhanced hepatotoxicity and the identifi-
cation of a unique panel of metabolites which reflected this syn-
ergistic effect, providing mechanistic insight of potential trans-
latable relevance for the clinical setting.
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Supplementary data are available online at http://toxsci.
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